Updating and expanding our flagship tool for measuring access to diagnosis and treatment across countries. The enhanced version includes new indicators for digital health access, mental health support, and patient quality of life.

International collaborative study examining mental health challenges, coping strategies, and support needs for people living with PIDs and their caregivers.

Comparing outcomes, quality of life, and patient preferences between home-based and hospital-based immunoglobulin replacement therapy.

A coordinated international effort to raise awareness of primary immunodeficiencies among healthcare professionals, policymakers, and the public.

Advocating for equitable access to immunoglobulin replacement therapy and supporting evidence-based policy frameworks worldwide.

Recomb is a multi-stakeholder research consortium aiming to advance a novel treatment for severe combined immunodeficiency (SCID) by conducting a clinical trial using gene therapy for one of the most common types of SCID: RAG1-SCID.